Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia : A retrospective case-control study
Zsófia Klára Németh, Anna Szűcs, József Vitrai, Dóra Juhász, János Pál Németh, Dr András Holló
Ideggyógyászati szemle, doi:10.18071/isz.74.0389
Az alábbi dokumentumot magáncélra töltötték le az eLitMed.hu webportálról. A dokumentum felhasználása a szerzôi jog szabályozása alá esik. Kulcsszavak: fluoxetin, COVID-19, SARS-CoV-2, pneumonia, túlélés, mortalitás score did not show statistical difference between the fluoxetine and non-fluoxetine groups supporting the reliability of our finding. Conclusion -Provisional to confirmation in randomised controlled studies, fluoxetine may be a potent treatment increasing the survival for COVID-19 pneumonia.
References
Baldwin, Woods, Lawson, Taylor, Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis, BMJ,
doi:10.1136/bmj.d1199Brambilla, Cipriani, Hotopf, Barbui, Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data, Pharmacopsychiatry,
doi:10.1055/s-2005-837806Carpinteiro, Edwards, Hoffmann, Kochs, Gripp et al., Pharmacological inhibition of acid sphin gomyelinase prevents uptake of SARS-CoV-2 by epithelial cells, Cell Rep Med,
doi:10.1016/j.xcrm.2020.100142Colombo, Colombo, Maves, Performance analysis of the national early warning score and modified early warning score in the adaptive COVID-19 Treatment Trial Cohort, Crit Care Explor
Creeden, Imami, Eby, Gillman, Becker et al., Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection, Biomed Pharmacother,
doi:10.1016/j.biopha.2021.111437Doupnik, Mitra, Feudtner, Marcus, The Influence of Comorbid Mood and Anxiety Disorders on Outcomes of Pediatric Patients Hospitalized for Pneumonia, Hosp Pediatr,
doi:10.1542/hpeds.2015-0177Ely, Dittus, Girard, Point: should benzodiazepines be avoided in mechanically ventilated patients? Yes, Chest,
doi:10.1378/chest.12-1189Fred, Kuivanen, Ugurlu, Casarotto, Levanov et al., Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro, bioRxiv,
doi:10.1101/2021.03.22.436379Glebov, Low-dose fluvoxamine modulates endocytic trafficking of SARS-CoV-2 spike protein: a potential mechanism for anti-COVID-19 protection by antidepressants, bioRxiv,
doi:10.1101/2021.06.15.448391Gordon, Hiatt, Bouhaddou, Rezelj, Ulferts et al., Comparative host-coronavirus protein inter action networks reveal pan-viral disease mechanisms, Science,
doi:10.1126/science.abe9403Hashimoto, Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor, Eur Arch Psychiatry Clin Neurosci,
doi:10.1007/s00406-020-01231-xHiles, Baker, De Malmanche, Attia, Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis, Psychol Med,
doi:10.1017/S0033291712000128Hoertel, Sánchez-Rico, Vernet, Beeker, Jannot et al., Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, Mol Psychiatry,
doi:10.1038/s41380-021-01021-4Jakubovski, Johnson, Nasir, Müller-Vahl, Bloch, Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders, Depress Anxiety,
doi:10.1002/da.22854Laporte, Chapelle, Caillet, Beyens, Bellet et al., Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies, Pharmacol Res,
doi:10.1016/j.phrs.2016.08.017Larici, Cicchetti, Marano, Bonomo, Storto, COVID-19 pneumonia: current evidence of chest imaging features, evolution and prognosis, Chin J Acad Radiol,
doi:10.1007/s42058-021-00068-0Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2020.22760Lundström, Isaksson, Näsman, Wester, Mår Tensson et al., Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial, Lancet Neurol,
doi:10.1016/S1474-4422(20)30219-2Obiora, Hubbard, Sanders, Myles, The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort, Thorax,
doi:10.1136/thoraxjnl-2012-202374Pérez-Cano, Moreno-Murguía, Morales-López, Crow-Buchanan, English et al., Anxiety, depression, and stress in response to the coronavirus disease-19 pandemic, Cir,
doi:10.24875/CIRU.20000561Rosen, Seki, Fernández-Castañeda, Beiter, Eccles et al., Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis, Sci Transl Med,
doi:10.1126/scitranslmed.aau5266Samuel, Seifert, Risk of bleeding in patients on fulldose enoxaparin with venous thromboembolism and selective serotonin reuptake inhibitors, Ann Pharmacother,
doi:10.1177/1060028016677309Schloer, Brunotte, Goretzko, Mecate-Zambrano, Korthals et al., Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine, Emerg Microbes Infect,
doi:10.1080/22221751.2020.1829082Schloer, Brunotte, Mecate-Zambrano, Zheng, Tang et al., Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro, Br J Pharmacol,
doi:10.1111/bph.15418Sed, El-Khouly, Bar, Am, Ghorab, Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection, Pharmaceutics,
doi:10.1016/j.ijpharm.2021.121023Starke, Reissig, Petereit-Haack, Schmauder, Nienhaus et al., The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis, medRxiv,
doi:10.1101/2021.05.27.21257909Sukhatme, Reiersen, Vayttaden, Sukhatme, Flu voxamine: a review of its mechanism of action and its role in COVID-19, Front Pharmacol,
doi:10.3389/fphar.2021.652688Sultana, Crisafulli, Gabbay, Lynn, Shakir et al., Challenges for drug repurposing in the COVID-19 pandemic era, Front Pharmacol,
doi:10.3389/fphar.2020.588654Taylor, Freemantle, Geddes, Bhagwagar, Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis, Arch Gen Psychiatry,
doi:10.1001/archpsyc.63.11.1217Vai, Mazza, Colli, Foiselle, Allen et al., Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis, Lancet Psychiatry,
doi:10.1016/S2215-0366(21)00232-7Wang, Li, Shi, Que, Liu et al., Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies, Mol Psychiatry,
doi:10.1038/s41380-019-0595-xWatkins, Koch, Sherwood, Blumenthal, Davidson et al., Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease, J Am Heart Assoc,
doi:10.1161/JAHA.112.000068Zimniak, Kirschner, Hilpert, Geiger, Danov et al., The serotonin reuptake inhibitor fluoxetine inhibits SARS-CoV-2 in human lung tissue, Sci Rep,
doi:10.1038/s41598-021-85049-0Çağlar, Kaçer, Anxiety levels in patients admitted to the emergency department with myocardial infarction or COVID-19 pneumonia, Psychol Health Med,
doi:10.1080/13548506.2021{ 'indexed': {'date-parts': [[2021, 12, 2]], 'date-time': '2021-12-02T11:42:23Z', 'timestamp': 1638445343842},
'reference-count': 0,
'publisher': 'Ideggyogyaszati Szemle Journal',
'issue': '11-12',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'short-container-title': ['Ideggyogy Sz'],
'published-print': {'date-parts': [[2021]]},
'abstract': '<jats:p>We aimed to investigate the association between fluoxetine use and the survival of '
'hospitalised coronavirus disease (COVID-19) pneumonia patients. This retrospective '
'case-control study used data extracted from the medical records of adult patients '
'hospitalised with moderate or severe COVID-19 pneumonia at the Uzsoki Teaching Hospital of '
'the Semmelweis University in Budapest, Hungary between 17 March and 22 April 2021. As a part '
'of standard medical treatment, patients received anti-COVID-19 therapies as favipiravir, '
'remdesivir, baricitinib or a combination of these drugs; and 110 of them received 20 mg '
'fluoxetine capsules once daily as an adjuvant medication. Multivariable logistic regression '
'was used to evaluate the association between fluoxetine use and mortality. For excluding a '
'fluoxetine-selection bias potentially influencing our results, we compared baseline '
'prognostic markers in the two groups treated versus not treated with fluoxetine. Out of the '
'269 participants, 205 (76.2%) survived and 64 (23.8%) died between days 2 and 28 after '
'hospitalisation. Greater age (OR [95% CI] 1.08 [1.05–1.11], p<0.001), radiographic '
'severity based on chest X-ray (OR [95% CI] 2.03 [1.27–3.25], p=0.003) and higher score of '
'shortened National Early Warning Score (sNEWS) (OR [95% CI] 1.20 [1.01-1.43], p=0.04) were '
'associated with higher mortality. Fluoxetine use was associated with an important (70%) '
'decrease of mortality (OR [95% CI] 0.33 [0.16–0.68], p=0.002) compared to the non-fluoxetine '
'group. Age, gender, LDH, CRP, and D-dimer levels, sNEWS, Chest X-ray score did not show '
'statistical difference between the fluoxetine and non-fluoxetine groups supporting the '
'reliability of our finding. Provisional to confirmation in randomised controlled studies, '
'fluoxetine may be a potent treatment increasing the survival for COVID-19 pneumonia.</jats:p>',
'DOI': '10.18071/isz.74.0389',
'type': 'journal-article',
'created': {'date-parts': [[2021, 12, 1]], 'date-time': '2021-12-01T11:12:43Z', 'timestamp': 1638357163000},
'page': '389-396',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': [ 'Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia : A '
'retrospective case-control study'],
'prefix': '10.18071',
'volume': '74',
'author': [ {'given': 'Zsófia Klára', 'family': 'Németh', 'sequence': 'first', 'affiliation': []},
{'given': 'Anna', 'family': 'Szűcs', 'sequence': 'additional', 'affiliation': []},
{'given': 'József', 'family': 'Vitrai', 'sequence': 'additional', 'affiliation': []},
{'given': 'Dóra', 'family': 'Juhász', 'sequence': 'additional', 'affiliation': []},
{'given': 'János Pál', 'family': 'Németh', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-8855-0469',
'authenticated-orcid': False,
'given': 'András',
'family': 'Holló',
'sequence': 'additional',
'affiliation': []}],
'member': '7411',
'published-online': {'date-parts': [[2021]]},
'container-title': ['Ideggyógyászati szemle'],
'original-title': [],
'deposited': { 'date-parts': [[2021, 12, 1]],
'date-time': '2021-12-01T11:12:47Z',
'timestamp': 1638357167000},
'score': 1,
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021]]},
'references-count': 0,
'journal-issue': { 'issue': '11-12',
'published-online': {'date-parts': [[2021]]},
'published-print': {'date-parts': [[2021]]}},
'URL': 'http://dx.doi.org/10.18071/isz.74.0389',
'relation': {},
'ISSN': ['0019-1442', '2498-6208'],
'issn-type': [{'value': '0019-1442', 'type': 'print'}, {'value': '2498-6208', 'type': 'electronic'}],
'subject': ['Clinical Neurology', 'Neurology'],
'published': {'date-parts': [[2021]]}}
